- Home
- PRPH vs LIXT Comparison
PRPH vs LIXT Comparison
Compare PRPH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- LIXT
- Stock Information
- Founded
- PRPH 1989
- LIXT 2005
- Country
- PRPH United States
- LIXT United States
- Employees
- PRPH N/A
- LIXT N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- LIXT Health Care
- Exchange
- PRPH Nasdaq
- LIXT Nasdaq
- Market Cap
- PRPH 21.9M
- LIXT 20.5M
- IPO Year
- PRPH 1997
- LIXT N/A
- Fundamental
- Price
- PRPH $0.28
- LIXT $4.20
- Analyst Decision
- PRPH
- LIXT
- Analyst Count
- PRPH 0
- LIXT 0
- Target Price
- PRPH N/A
- LIXT N/A
- AVG Volume (30 Days)
- PRPH 1.3M
- LIXT 75.1K
- Earning Date
- PRPH 11-07-2025
- LIXT 11-07-2025
- Dividend Yield
- PRPH N/A
- LIXT N/A
- EPS Growth
- PRPH N/A
- LIXT N/A
- EPS
- PRPH N/A
- LIXT N/A
- Revenue
- PRPH $5,588,000.00
- LIXT N/A
- Revenue This Year
- PRPH $221.82
- LIXT N/A
- Revenue Next Year
- PRPH N/A
- LIXT N/A
- P/E Ratio
- PRPH N/A
- LIXT N/A
- Revenue Growth
- PRPH N/A
- LIXT N/A
- 52 Week Low
- PRPH $0.22
- LIXT $0.64
- 52 Week High
- PRPH $0.93
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- PRPH 35.09
- LIXT 45.52
- Support Level
- PRPH $0.26
- LIXT $4.20
- Resistance Level
- PRPH $0.29
- LIXT $4.97
- Average True Range (ATR)
- PRPH 0.03
- LIXT 0.36
- MACD
- PRPH -0.01
- LIXT 0.02
- Stochastic Oscillator
- PRPH 21.42
- LIXT 33.19
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.